FDA Greenlights Regeneron Antibody Treatment Given To Trump

By Staff Reporter
Posted on 11/22/20 | News Source: i24

Regeneron's treatment reduced COVID-19-related hospitalizations or emergency room visits in patients

The US Food and Drug Administration (FDA) approved the use of a COVID-19 treatment given to US President Donald Trump after he was diagnosed with the disease in October for people who aren't yet hospitalized by the disease but are at high risk.

Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

The green light for drugmaker Regeneron came after REGEN-COV2, a combination of two lab-made antibodies, was shown to reduce COVID-19-related hospitalizations or emergency room visits in patients with underlying conditions.

"Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system," said Stephen Hahn, commissioner of the Food and Drug Administration (FDA).

Leonard Schleifer, Regeneron's president and CEO, added the move was "an important step in the fight against COVID-19, as high-risk patients in the United States will have access to a promising therapy early in the course of their infection." Read more at i24